Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Stem cells are undifferentiated cells which are capable of differentiating into any type of cell that make-up the human body and thus, are capable of producing non-regenerative cells such as neural and myocardial cells.
The global stem cells market is estimated to account for US$ 9,941.2 Mn in terms of value in 2020 and is expected to reach US$ 18,289.9 Mn by the end of 2027.
Global Stem Cells Market: Drivers
Approval and launch of new products is expected to propel growth of the global stem cells market over the forecast period. For instance, in December 2019, BioRestorative Therapies, Inc. received a Notice of Allowance on its patent application for a method of generating brown fat stem cells from Israeli Patent Office.
Moreover, increasing number of stem cell banking resource centers is also expected to aid in growth of the market. For instance, in March 2020, Stemlife Berhad, a cord blood bank in Malaysia, started a Stem Cell Banking Resource Center in Jerudong Park Medical Center, Brunei.
Adult stem cells held dominant position in the global stem cells market in 2019, accounting for 81.2% share in terms of value, followed by Human Embryonic Stem Cells and Induced Pluripotent Stem Cells, respectively
Figure 1. Global Stem Cells Market Share (%), by Value, by Cell Type, 2019.
Global Stem Cells Market: Restraints
High cost of stem cell therapy is expected to hinder growth of the global stem cells market. For instance, Bioinformant— a research firm engaged in stem cell research, reported that the cost of stem cell therapy ranges between US$ 5,000-8,000 per patient and in some cases it may rise as much as US$ 25,000 or more depending on the complexity of the procedure.
Moreover, restrictions on research activities related to stem cells had hampered the growth of embryonic stem cells historically and resulted in its meager share in the total market in spite of its advantages over adult stem cells.
Stem Cells Market Report Coverage
||Market Size in 2020:
||US$ 9,941.2 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 18,289.9 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
- By Type: Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells, Natural Rosette Cells, Very Small Embryonic Like Stem Cells.
- By Application: Regenerative Medicine, Drug Discovery and Development.
- By Technology: Cell Acquisition, Cell Production, Cryopreservation, Expansion and Sub-Culture.
Advanced Cell Technology, Inc., Angel Biotechnology Holdings PLC, Bioheart Inc., Lineage Cell Therapeutics., BrainStorm Cell Therapeutics, Inc., California Stem Cell Inc., Celgene Corporation, Takara Bio Europe AB, Cellular Engineering Technologies, Cytori Therapeutics Inc., Osiris Therapeutics, and STEMCELL Technologies Inc
- Increasing research and development
- Increasing applications of regenerative medicine
|Restraints & Challenges:
- High costs
- Lack of skilled professionals
Global Stem Cells Market: Opportunities
R&D in stem cell donation is expected to offer lucrative growth opportunities for players in the global stem cells market. For instance, in March 2020, researchers from Dankook University and Catholic University, South Korea, reported investigation of the types and degrees of physical and psychological discomfort experienced by hematopoietic stem cell donors before, during, and after the donation process.
Moreover, adoption of online distribution channel is also expected to aid in growth of the global stem cells market. For instance, “The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions”, published in the journal Perspectives in Biology and Medicine, in 2018, the number of new stem cell businesses with websites doubled on average every year between 2009 and 2014, in the U.S.
The global stem cells market was valued at US$ 9,112.0 Mn in 2019 and is forecast to reach a value of US$ 18,289.9 Mn by 2027 at a CAGR of 9.1% between 2020 and 2027.
Figure 2. Global Stem Cells Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Adoption of stem cells for the treatment of various diseases is expected to propel growth of the global stem cells market. For instance, in January 2020, researchers at University of Houston developed biologic cardiac pacemaker-like cells by taking fat stem cells and reprogramming them as an alternative treatment for heart conditions such as conduction system disorders and heart attacks.
Moreover, increasing investment in stem cell therapies is also expected to aid in growth of the market. For instance, in July 2018, the Emory Orthopaedics & Spine Center, in collaboration with Sanford Health, Duke University, Andrews Institute, and Georgia Institute of Technology, received US$ 13 million grant from the Marcus Foundation for a multicenter clinical trial studying stem cell options for treating osteoarthritis. The Phase 3 trial was initiated in March 2019, and is expected to complete by December 2021.
Global Stem Cells Market: Competitive Landscape
Major players operating in the global stem cells market include, Advanced Cell Technology, Inc., Angel Biotechnology Holdings PLC, Bioheart Inc., Lineage Cell Therapeutics., BrainStorm Cell Therapeutics, Inc., California Stem Cell Inc., Celgene Corporation, Takara Bio Europe AB, Cellular Engineering Technologies, Cytori Therapeutics Inc., Osiris Therapeutics, and STEMCELL Technologies Inc.
Global Stem Cells Market: Key Developments
Major players in the market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in September 2018, STEMCELL Technologies signed an exclusive license agreement with Brigham and Women’s Hospital for rights to commercialize technologies for the generation of human pluripotent stem cell-derived kidney organoids.